The success of Viagra initially sparked a boom for pharma, however recent changes present a uncertain scenario for shareholders. Generic alternatives are reducing profits, and ongoing patent challenges add further risk https://liliandolx701924.therainblog.com/39725287/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment